Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer Clinical Trial

Official title:

A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04923932
• Other study ID #: 2020-504-00CH1
• Status: Recruiting
• Phase: Phase 2
• Start date: July 27, 2021
• Est. completion date: October 2025

Study information

• Verified date: March 2023
• Source: Hutchmed
• Contact: Tinghua Song
• Phone: 19512230542
• Email: tinghuas[@]hutch-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib

Description:

This is a single-arm, multi-cohort, multi-center, open-label, phase II clinical study. The objective is to evaluate the efficacy and safety of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications. The study involves a Screening Period, a Treatment Period and a Follow-up Period. It is planned that about 30 study sites will enroll 75 patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: October 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure;

2. Age =18 years;

3. Histologically diagnosed locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma

4. MET gene amplifications

5. Cohort 1: Having measurable lesions (in accordance with RECIST 1.1 criteria); Cohort 2: having evaluable lesions

6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2

7. Survival is expected to exceed 12 weeks;

8. Adequate functionality in bone marrow, liver, kidney

9. Able to take or swallow the drug orally.

10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 30 days after discontinuation of the study drug,The male patients whose sexual partners are women of childbearing age must use condom during sexual intercourse during the study and within 6 months after discontinuation of study drug;

Exclusion Criteria:

1. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have small possibility of recurrence. Patients with radically treated carcinoma in situ (non-infiltrating) and skin cancer other than malignant melanoma can be enrolled;

2. Having received antitumor therapy (including chemotherapy, hormone therapy, biotherapy, immunotherapy or traditional Chinese medicine for antitumor indication) within 3 weeks prior to the start of study treatment, or having received treatment with small molecular tyrosine kinase inhibitors (e.g., EGFR-TKI) within 2 weeks prior to the start of study treatment;

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophagogastric Junction Disorder
• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Savolitinib
Patients meeting the study inclusion criteria will receive Savolitinib [Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight =50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight <50 kg] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.

Locations

Country	Name	City	State
China	Beijing Cancer Hopspital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria)	To evaluate the efficacy of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months
Secondary	Progression-free survival (PFS) (RECIST 1.1 criteria)	Efficacy of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months
Secondary	incidence of various adverse events (AE)	To evaluate the safety and tolerability of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications	through study completion, an average of 3.5 year